blinatumomab   Click here for help

GtoPdb Ligand ID: 7384

Synonyms: Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 [2]
Approved drug Immunopharmacology Ligand
blinatumomab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Blinatumomab is a monoclonal antibody with anti-cancer effects. Its mechanism of action classifies this antibody as a member of the bi-specific T-cell engager (BiTE®) group of engineered antibodies. It was the first biologic of this class to gain clinical approval.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
Blinatumomab is an immuno-oncology agent.
Immunopharmacology Disease
Disease X-Refs Comment References
Acute lymphocytic leukemia (ALL) OMIM: 613065
 Approved specifically for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.